Why Iovance Biotherapeutics (IOVA) Stock Is Down Today

Iovance Biotherapeutics (IOVA) is down 6.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely explanation is profit-taking after a very sharp rally late last month, rather than a clearly new negative headline today. The company’s most recent filing on October 5 only disclosed an updated corporate presentation, while the bigger recent catalyst was the September 29 guidance increase that had already pushed the stock sharply higher. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1425205/000110465926113763/tm2627047d1_8k.htm))

Details:

Shares opened near the prior close and then slid during the session, with the stock trading about 6.7% lower intraday on October 6.

On September 29, the company raised full-year 2026 revenue guidance to $410 million to $420 million, driven by strong U.S. demand for Amtagvi and Proleukin. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1425205/000110465926111583/tm2626507d1_ex99-1.htm?utm_source=openai))

That guidance update had already sparked a 31.5% one-day jump on September 29, followed by prices holding near recent highs, which can set up a pullback as traders lock in gains. This could be because the earlier rally had moved too far, too fast. ([stockanalysis.com](https://stockanalysis.com/stocks/iova/history/?utm_source=openai))

A separate overhang is overseas regulatory uncertainty: the European Medicines Agency page shows the company withdrew its Amtagvi marketing application in Europe, which may still temper sentiment even if it does not appear to be the direct trigger for today’s drop. ([ema.europa.eu](https://www.ema.europa.eu/en/medicines/human/EPAR/amtagvi?utm_source=openai))

Sources:

SEC, Nasdaq, European Medicines Agency

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive IOVA Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$IOVA Hedge Fund Activity

We have seen 160 institutional investors add shares of $IOVA stock to their portfolio, and 93 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

INVENOMIC CAPITAL MANAGEMENT LP removed 7,012,956 shares (-82.5%) from their portfolio in Q2 2026, for an estimated $29,173,896
BLACKROCK, INC. added 5,877,176 shares (+18.9%) to their portfolio in Q2 2026, for an estimated $24,449,052
TWO SIGMA INVESTMENTS, LP added 5,323,264 shares (+38.9%) to their portfolio in Q2 2026, for an estimated $22,144,778
JUPITER ASSET MANAGEMENT LTD added 4,535,080 shares (+inf%) to their portfolio in Q2 2026, for an estimated $18,865,932
DIMENSIONAL FUND ADVISORS LP added 3,814,747 shares (+144.2%) to their portfolio in Q2 2026, for an estimated $15,869,347
GOLDMAN SACHS GROUP INC removed 3,663,726 shares (-41.8%) from their portfolio in Q2 2026, for an estimated $15,241,100
BANK OF AMERICA CORP /DE/ removed 3,496,535 shares (-41.2%) from their portfolio in Q2 2026, for an estimated $14,545,585

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.